ACTU Stock — Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc. Common stock (ACTU)

Updated October 16, 2026.

ACTU is a Stock. Total return is -93.0% over the past 2.2 years, 137.5 points behind SPY at 44.5%.

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies, with its lead candidate elraglusib injection in Phase 2 trials for metastatic pancreatic cancer and Phase 1/2 trials for pediatric malignancies including Ewing sarcoma and neuroblastoma. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage oncology drug development, though clinical-stage biotech carries substantial risk with no guarantee of regulatory approval or commercialization.

ACTU performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.0% over the past 2.2 years, 137.5 points behind SPY at 44.5%. Over the past year its total return — price change plus distributions reinvested — is -92.2%. Its deepest 1-year drawdown was 94.4%.

ACTU key facts

Asset type

Stock

Asset class

Equity

Inception date

08/13/2024

Distribution frequency

None

Last close

$0.60 (as of 2026-10-16)

Market cap

$14,528,592

Average volume

884743.0

Beta

1.2

Payout ratio

0.0%

EPS

$-0.87

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACTU risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 94.4%.

Who may consider ACTU — and who may not

It is a weaker fit for investors who need monthly cash flow (ACTU does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACTU

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions